BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND NFATC2, ENSG00000101096, 4773, Q13469, NFATP, NFAT1, KIAA0611 AND Treatment
8 results:

  • 1. Report and literature review of four cases of EWSR1::nfatc2 round cell sarcoma.
    Liu L; Li L; Ding Y; Kong F; Mo W; Ye H; Shen D
    Diagn Pathol; 2024 Jan; 19(1):19. PubMed ID: 38254207
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Osteopontin isoform c promotes the survival of cisplatin-treated NSCLC cells involving nfatc2-mediated suppression on calcium-induced ROS levels.
    Huang J; Hu M; Niu H; Wang J; Si Y; Cheng S; Ding W
    BMC Cancer; 2021 Jun; 21(1):750. PubMed ID: 34187410
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Restricting extracellular Ca2+ on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca2+ response, which consequently enhances gefitinib sensitivity.
    Kim MS; Kim SH; Yang SH; Kim MS
    PLoS One; 2020; 15(8):e0238155. PubMed ID: 32841278
    [TBL] [Abstract] [Full Text] [Related]  

  • 4.
    Jreige M; Letovanec I; Chaba K; Renaud S; Rusakiewicz S; Cristina V; Peters S; Krueger T; de Leval L; Kandalaft LE; Nicod-Lalonde M; Romero P; Prior JO; Coukos G; Schaefer N
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1859-1868. PubMed ID: 31214790
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. nfatc2 enhances tumor-initiating phenotypes through the nfatc2/SOX2/ALDH axis in lung adenocarcinoma.
    Xiao ZJ; Liu J; Wang SQ; Zhu Y; Gao XY; Tin VP; Qin J; Wang JW; Wong MP
    Elife; 2017 Jul; 6():. PubMed ID: 28737489
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A key regulatory role of the transcription factor nfatc2 in bronchial adenocarcinoma via CD8+ T lymphocytes.
    Maxeiner JH; Karwot R; Sauer K; Scholtes P; Boross I; Koslowski M; Türeci O; Wiewrodt R; Neurath MF; Lehr HA; Finotto S
    Cancer Res; 2009 Apr; 69(7):3069-76. PubMed ID: 19318584
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
    Chang MH; Kim KH; Jun HJ; Kim HS; Yi SY; Uhm JE; Park MJ; Lim DH; Ji SH; Hwang IG; Lee J; Park YH; Ahn JS; Ahn MJ; Park K
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):917-24. PubMed ID: 19221753
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer.
    Sabater L; Bataller L; Carpentier AF; Aguirre-Cruz ML; Saiz A; Benyahia B; Dalmau J; Graus F
    J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1359-62. PubMed ID: 16801349
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.